New York University

Puretech Health, LLC

Yale University

Puretech Lyt, Inc.

Argenx Iip Bv

Novartis Ag

Research Corporation Technologies, Inc.

Shohei Koide

Akiko Koide

George Miller

Joseph Beene Bolen

Eric Elenko

Aleksandra Filipovic

Linxiao Chen

Takamitsu Hattori

Tatyana Panchenko

Kai Wen Teng

Christophe Blanchetot

Karen Silence

W Mark Saltzman

Jordan S Pober

Steven J Burden

Claire Albert

Gregory T Tietjen

Laura Bracaglia

Carmine Fedele

Lorenzo Maso

Benjamin Neel

Nadia Leloup

Julien Oury

Roeland Vanhauwaert

Provided are compositions and methods that include binding partners that bind with specificity to target sites on proteins or peptides that comprise a covalently attached molecule. The binding partners are provided as antibodies and antibody derivatives that specifically bind to proteins and peptides that have been covalently modified by attachment of a molecule, such as a drug. The binding partners can bind with specificity to covalently modified peptides when presented in the context of a major histocompatibility complex (MHC). Uses of the compositions and methods for prophylaxis or therapy of disorders are also provided.

Compositions and methods comprising antibodies that bind to covalent peptide conjugates

A platform technology provides particle and nucleic acid conjugates, and compositions thereof, with enhanced targeting to cells, tissues, organs. The particles and nucleic acids and other deliverables contain a synthetic binding protein such as a polypeptide monobody covalently conjugated to the surface of the particle or the nucleic acid, for linking a targeting agent to the particle's surface or the nucleic acid. The particles and nucleic acids and other deliverables optionally contain an antibody non-covalently conjugated to the binding protein, via an Fc domain of the antibody. The particles can include therapeutic agents, diagnostic agents, prophylactic agents, or a combination thereof, to be delivered to desired cells, tissues, and/or organs. The particles and nucleic acids and other deliverables can be used in a wide array of applications including, but not limited to, ex vivo perfusion of mammalian organs and in vivo disease treatment.

Enhanced targeting platform

Disclosed herein are antibodies specific to a delta-1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells.

Antibodies specific to delta 1 chain of T cell receptor

Provided are proteins or peptides, which may be referred to as monobodies. Fusion proteins and proteolysis targeting chimeras (PROTACs) comprising the proteins or peptides are also provided. Also provided are compositions of the proteins or peptides of the present disclosure, as well as compositions of fusion proteins and compositions of PROTACs. Methods of treating an individual in need of treatment are also provided. The methods may be to treat an individual suffering from or suspected of having KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. A method may be for inhibiting ERK activation and/or proliferation of KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers.

Selective and noncovalent inhibitors of oncogenic RAS mutants

Disclosed herein are antibodies specific to a delta1 chain of a &#x3b3;&#x3b4; T cell receptor and methods of using such for modulating &#x3b3;&#x3b4; T cell bioactivity. Such anti-Delta1 antibodies may also be used to treat diseases associated with &#x3b3;&#x3b4; T cell activation, such as solid tumors, or for detecting presence of &#x3b3;&#x3b4;1 T cells.

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Anti-galectin-9 antibodies and uses thereof

The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.

Therapeutic musk antibodies

Anti-Galectin-9 antibodies and uses thereof

Growing community of inventors

New York, NY, United States of America

Shohei Koide